Completed PHASE4 INTERVENTIONAL 2-arm NCT03528967

Enoxaparin in the Prevention of Placental Insufficiency in Pregnant Women (PRESANCE)

Enoxaparine en PREvention Des insuffiSAnces Placentaires Chez Les Femmes eNCEintes

Sponsor: Les Laboratoires des Médicaments Stériles

Conditions Enoxaparin Placental Insufficiency

Interventions Aspirin 100 mg Oral Tablet, Enteric Coated Enoxaparin 40 mg / 0.4 mL Prefilled Syringe

Updated 6 times since 2018 Last updated: Jun 30, 2020 Started: Oct 23, 2013 Primary completion: Jul 31, 2018 Completion: Jul 31, 2018

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE4 clinical study on Enoxaparin and Placental Insufficiency, this trial is completed. The trial is conducted by Les Laboratoires des Médicaments Stériles and has accumulated 6 data snapshots since 2013. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE4
Jul 2024 — Sep 2024 [monthly]

Completed PHASE4
Jan 2021 — Jul 2024 [monthly]

Completed PHASE4
Aug 2020 — Jan 2021 [monthly]

Completed PHASE4
Sep 2018 — Aug 2020 [monthly]

Completed PHASE4

Status: Recruiting → Completed

▶ Show 1 earlier version

Jun 2018 — Sep 2018 [monthly]

Recruiting PHASE4

First recorded

Oct 2013

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Les Laboratoires des Médicaments Stériles

Data source: Les Laboratoires des Médicaments Stériles

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Tunis, Tunisia